Acurx Pharmaceuticals (NASDAQ:ACXP) Announces Quarterly Earnings Results, Misses Expectations By $0.15 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its quarterly earnings data on Friday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.15), FiscalAI reports.

Here are the key takeaways from Acurx Pharmaceuticals’ conference call:

• FDA guidance supports a potential approval pathway for ibezapolstat through the planned single Phase III IBZ-ASPIRE trial, provided the overall clinical evidence is robust; the FDA may also consider data from the 20-patient PATHFINDER study at a pre-NDA meeting.
• The fully funded PATHFINDER trial in recurrent C. difficile infection is expected to begin enrollment in the fourth quarter of 2026, and management said it has sufficient API and formulated product to support both PATHFINDER and a future ASPIRE trial.
• Acurx still needs public or private funding, partnerships, or other financing to launch ASPIRE, an international Phase III trial. The company raised capital through stock and warrant offerings, which provided resources for at least a year but created potential dilution.
• Second-quarter cash was $10.7 million, while the company reported a $2.3 million quarterly net loss; R&D spending increased to $1.1 million as manufacturing and recurrent-CDI trial costs rose, partly offset by lower general and administrative expenses.
• Acurx received conditional FDA acceptance and USPTO trademark allowance for ibezapolstat’s proposed brand name, Syfbezi, and reported additional patent, microbiome, and DNA Pol IIIC research progress that could support the drug’s commercial and broader antibiotic pipeline potential.

Acurx Pharmaceuticals Stock Down 5.7%

ACXP opened at $1.40 on Friday. The stock has a market capitalization of $6.00 million, a price-to-earnings ratio of -0.52 and a beta of -2.03. The firm has a 50 day moving average price of $1.52 and a 200-day moving average price of $2.20. Acurx Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $8.34.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ACXP. Armistice Capital LLC purchased a new stake in Acurx Pharmaceuticals during the 2nd quarter valued at $551,000. Geode Capital Management LLC bought a new position in shares of Acurx Pharmaceuticals during the 4th quarter valued at $31,000. Jane Street Group LLC purchased a new position in shares of Acurx Pharmaceuticals in the 4th quarter worth $27,000. Finally, Millennium Management LLC purchased a new position in shares of Acurx Pharmaceuticals in the 4th quarter worth $103,000. Institutional investors own 11.53% of the company’s stock.

Wall Street Analyst Weigh In

ACXP has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen upgraded Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $31.00.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).